AFATINIB (AFATIN) TABLET

Feature:

1. Targeted Therapy: Afatinib is a tyrosine kinase inhibitor (TKI) that targets and blocks the activity of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), proteins that are overexpressed in some cancer cells.
2. Multiple Strengths: Available in 20mg, 30mg, and 40mg strengths to accommodate individual patient needs and treatment plans.
3. Non-Small Cell Lung Cancer (NSCLC): Approved for the treatment of NSCLC with specific mutations in the EGFR gene, including exon 19 deletions or exon 21 (L858R) substitution mutations.
4. Metastatic Breast Cancer: Used in combination with other medications for the treatment of metastatic breast cancer that overexpresses HER2 (HER2-positive).
5. Oral Administration: Administered orally once daily, typically on an empty stomach, at least one hour before or two hours after a meal.
6. Efficacy: Demonstrated efficacy in prolonging progression-free survival and overall survival in clinical trials for both NSCLC and metastatic breast cancer.
7. Side Effects: Common side effects may include diarrhea, rash, mucositis (inflammation of the mouth and throat), and fatigue. Patients should be monitored closely for adverse reactions.
8. Patient Education: Patients should be counseled on proper medication administration, potential side effects, and the importance of adherence to treatment.
9. Consultation with Healthcare Provider: Treatment with Afatinib should be initiated and monitored by a qualified oncologist experienced in the management of cancer.
10. Access and Affordability: Efforts should be made to ensure access to this medication for eligible patients, including exploring financial assistance programs and insurance coverage options.